Aptiv Solutions Acquires SRA Global Clinical Development
Aptiv Solution announced it has acquired SRA Global Clinical Development (GCD), the CRO division of SRA International, Inc. based in Durham, N.C., with offices in Paris, France and Milton Park, England.
SRA GCD and its predecessor companies have built a substantial business by delivering high-quality clinical trial and regulatory services around the globe. SRA GCD’s regulatory consulting team based near London adds significantly to the Aptiv Solutions regulatory services group. The additional talent from SRA GCD accelerates Aptiv Solutions leadership in regulatory services.
“We believe the GCD business, as a part of Aptiv Solutions, has greater opportunity to pursue a wider range of initiatives that align with its mission,” said SRA President and CEO Bill Ballhaus
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
